<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-147108</identifier>
<setSpec>1699-258X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">How to optimize the antiTNF alpha therapy in spondylitis?</dc:title>
<dc:description xml:lang="en">TNFalpha inhibitors have been a major advance in the treatment of spondyloarthropathies, having demonstrated their safety and efficacy, with higher response and survival rates than those observed in patients with rheumatoid arthritis. The fact that disease modifying anti-arthritic drugs (DMARD) have shown utility in the treatment of this disease, especially in the axial forms, gives them greater importance, since it is known that up to 30%of patients do not respond to treatment with non-steroidal anti-inflammatory drugs. However, we must take into account that these drugs are expensive and not without side effects, so it is necessary to optimize their use. We intend to review the use of antiTNF alpha in spondyloarthropathies and review the available evidence on strategies that can help with their rational use (AU)</dc:description>
<dc:creator>Castro Villegas, Maria del Carmen</dc:creator>
<dc:creator>Escudero Contreras, Alejandro</dc:creator>
<dc:creator>Miranda García, Maria Dolores</dc:creator>
<dc:creator>Collantes Estévez, Eduardo</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Los inhibidores del TNFalfa (antiTNFalfa) han supuesto un avance importante en el tratamiento de las espondiloartropatías, habiendo demostrado su eficacia y seguridad, con tasas de respuesta y supervivencia incluso superiores a las observadas en pacientes con artritis reumatoide. El hecho de que los fármacos modificadores de la enfermedad (FAME) no han mostrado utilidad en el tratamiento de esta patología, especialmente en las formas axiales, les confiere mayor importancia, dado que se sabe que hasta el 30% de los pacientes no responden al tratamiento con antiinflamatorios no esteroideos. Sin embargo, hay que tener en cuenta que son fármacos caros y no exentos de efectos secundarios, por lo que es necesario un uso óptimo. Pretendemos hacer una revisión del uso de antiTNFalfa en las espondiloartropatías y se plantean las evidencias disponibles sobre estrategias que puedan ayudar a su uso racional (AU)</dc:description>
<dc:source>Reumatol. clín. (Barc.);8(supl.1): 26-31, mar. 2012.</dc:source>
<dc:identifier>ibc-147108</dc:identifier>
<dc:title xml:lang="es">¿Cómo optimizar la terapia antiTNFalfa en las espondiloartritis?</dc:title>
<dc:subject>^d308^s22000</dc:subject>
<dc:subject>^d28634</dc:subject>
<dc:subject>^d29591^s22006</dc:subject>
<dc:subject>^d23695^s22012</dc:subject>
<dc:subject>^d23695^s22057</dc:subject>
<dc:subject>^d32095</dc:subject>
<dc:subject>^d27938^s22073</dc:subject>
<dc:subject>^d32355^s22020</dc:subject>
<dc:subject>^d12835^s22073</dc:subject>
<dc:subject>^d14384</dc:subject>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d906^s22073</dc:subject>
<dc:subject>^d15007^s22057</dc:subject>
<dc:subject>^d28622</dc:subject>
<dc:subject>^d36004^s22057</dc:subject>
<dc:subject>^d308^s22073</dc:subject>
<dc:subject>^d36004^s22012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d12002^s22057</dc:subject>
<dc:subject>^d22164</dc:subject>
<dc:subject>^d4419</dc:subject>
<dc:subject>^d12002^s22012</dc:subject>
<dc:subject>^d12835^s22000</dc:subject>
<dc:subject>^d29431^s22020</dc:subject>
<dc:subject>^d906^s22000</dc:subject>
<dc:subject>^d15007^s22012</dc:subject>
<dc:subject>^d32355^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>201203</dc:date>
</metadata>
</record>
</ibecs-document>
